Is Participation in Cancer Phase I Trials Really Therapeutic?
Open Access
- 10 January 2017
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (2), 135-138
- https://doi.org/10.1200/jco.2016.67.9902
Abstract
No abstract availableThis publication has 41 references indexed in Scilit:
- Publication and Reporting Conduct for Pharmacodynamic Analyses of Tumor Tissue in Early-Phase Oncology TrialsClinical Cancer Research, 2012
- Raise standards for preclinical cancer researchNature, 2012
- Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatmentHealth and Quality of Life Outcomes, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave RoussyAnnals Of Oncology, 2007
- Phase I research and the meaning of direct benefitThe Journal of Pediatrics, 2006
- Objective Response Rate As a Surrogate End Point: A CommentaryJournal of Clinical Oncology, 2005
- Objective Response to Chemotherapy As a Potential Surrogate End Point of Survival in Metastatic Breast Cancer PatientsJournal of Clinical Oncology, 2005
- Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002The New England Journal of Medicine, 2005